Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · November 02, 2016

cTnI and cTnT and NT-proBNP for Monitoring Cardiac Safety of Patients With Early-Stage HER2-Positive Breast Cancer Taking Trastuzumab

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
J. Clin. Oncol 2016 Oct 23;[EPub Ahead of Print], D Zardavas, TM Suter, DJ Van Veldhuisen, J Steinseifer, J Noe, S Lauer, N Al-Sakaff, MJ Piccart-Gebhart, E de Azambuja

Further Reading